Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

7.4%

14 terminated/withdrawn out of 189 trials

Success Rate

92.1%

+5.6% vs industry average

Late-Stage Pipeline

51%

97 trials in Phase 3/4

Results Transparency

24%

40 of 164 completed trials have results

Key Signals

40 with results13 terminated

Enrollment Performance

Analytics

Phase 3
97(52.4%)
Phase 2
51(27.6%)
Phase 1
28(15.1%)
N/A
9(4.9%)
185Total
Phase 3(97)
Phase 2(51)
Phase 1(28)
N/A(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (189)

Showing 20 of 189 trials
NCT00310180Phase 3Active Not Recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Role: collaborator

NCT00428142Phase 2Completed

Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Role: lead

NCT00066443Phase 1Completed

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Role: lead

NCT00003140Phase 3Completed

Letrozole After Tamoxifen in Treating Women With Breast Cancer

Role: lead

NCT00003641Phase 3Active Not Recruiting

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Role: collaborator

NCT00066690Phase 3Completed

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Role: collaborator

NCT00049595Phase 3Completed

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Role: collaborator

NCT00476190Phase 2Completed

ALL Adult Consortium Trial: Adult ALL Trial

Role: collaborator

NCT00667251Phase 3Completed

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Role: collaborator

NCT01924819Phase 2Active Not Recruiting

Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

Role: collaborator

NCT00324805Phase 3Completed

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Role: collaborator

NCT00930332Phase 1Terminated

Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain

Role: lead

NCT00482755Phase 2Completed

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Role: lead

NCT00411138Phase 3Unknown

Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer

Role: collaborator

NCT00049673Phase 3Completed

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Role: lead

NCT00626990Phase 3Active Not Recruiting

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

Role: collaborator

NCT01830621Phase 3Completed

BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma

Role: lead

NCT01248585Phase 3Completed

Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases

Role: lead

NCT00066573Phase 3Completed

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Role: lead

NCT00083174Phase 3Completed

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Role: lead